Assessing the sex-based enrollment gap in urologic oncology clinical trials
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: Clinical trials should reflect the population affected by the disease under study. While urologic cancers occur more frequently in men, there is still a substantial incidence in women. Ensuring representative enrollment by sex is crucial for trial generalizability, as treatment efficacy and safety may vary between men and women. However, whether women are proportionately represented in urologic oncology clinical trials is unknown. METHODS: We estimated the proportion of woman enrollees in bladder and kidney cancer trials with reported results registered on ClinicalTrials.gov since January 1, 2007 through the Aggregate Analysis of ClinicalTrials.gov database. Proportions of woman participants were extracted from result tables, grouped by cancer type, and compared to the proportion of incident cancers occurring in women estimated by the American Cancer Society. RESULTS: There were 638 cancer trials included in the analysis. The median proportion of women participants in kidney cancer trials was 29% (IQR 23%-38%) compared to an expected proportion of 36% of new kidney cancer cases incident in women, and only 28% of kidney cancer trials met or exceeded 36%-woman participants. Bladder cancer trials enrolled a median 24% women (IQR 17%-33%), similar to the proportion of bladder cancer cases incident in women (24%). CONCLUSIONS: Few kidney cancer trials enroll a representative number of women, while bladder cancer trials enroll as expected. Further work is needed to ensure adequate representation of women in urologic oncology trials to ensure equitable, safe, and effective treatments across sexes.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Assessing the sex-based enrollment gap in urologic oncology clinical trials
- Date Crossref
- 01/12/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Michigan Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Michigan State University pays non établi dans la noticeUniversité ou école supérieure
-
Sinclair Community College pays non établi dans la noticeUniversité ou école supérieure
-
University of Missouri Department of Family and Community Medicine pays non établi dans la noticeUniversité ou école supérieure
-
University of Chicago Division of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Michigan Medicine pays non établi dans la noticeÉtablissement de santé
Department of Urology — University of Michigan, Michigan State University et Sinclair Community College, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.